Compare Core Scientific Inc (CORZ) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Zoetis Inc — how do they compare? Core Scientific Inc trades at $20.3 (market cap $6.35B), while Zoetis Inc trades at $75.38 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 4.9× Core Scientific Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals.
| CORZ | ZTS | |
|---|---|---|
Market Cap | $6.35B | $31.14B |
Sector | Technology | Health |
52-Week High | $29.16 | $156.76 |
52-Week Low | $13.55 | $71.91 |
Enterprise Value | $8.88B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $21.18, up 8.95% in the last session, amid a technical bearish trend but strong analyst optimism. The company reported Q2 2026 revenue growth and a strategic AMD partnership for AI infrastructure, though it faces significant net losses and negative cash flow. Key support lies at $18, with resistance near $21.
The outlook is mixed: bullish analyst targets near $36 suggest upside potential from AI-driven contracts, but high cash burn and persistent losses pose risks. Investors should weigh growth prospects against financial sustainability, with sentiment hinging on execution of new deals and margin improvement.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
